This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.
of US adults received a vaccine, far short of the Healthy People 2030 target of 70%. Meet Communities Where They Are Although influenza vaccines are widely available, vaccination rates remain below national goals. During the 2023-2024 influenza season, only 44.9%
CAR T-cell therapies dominate the genetically modified space, targeting cancer in 97% of cases, while non-genetically modified therapies focus on regenerative medicine. Technological advances, such as CRISPR-Cas9 and in vivo cell engineering, are addressing challenges like short-term cell persistence and antigen escape.
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. A steady increase in CVD-related deaths resulted in approximately 18.6 1 CVDs are disorders affecting the heart and blood vessels.
What we know is that this is compounded and accelerated in people living with HIV.” With earlier initiation of menopause, Chandiwana explained that weight gain can be heightened and lead to a greater effect on mobility and activities of daily living. 1 “Obesity and overweight is associated with over 200 diseases,” Chandiwana discussed.
million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L.
4,5 In most cases, HPV infections are short-lived and resolve on their own within 1 to 2 years, as the immune system clears the virus. The risk of acquiring a high-risk HPV type is higher among those who become sexually active at a young age, particularly those under 18 years of age or who have multiple sexual partners.
Buy Reports Newsletters PT Analysis Left Right Features Comment & Opinion Data Insights Analyst Comment US eosinophilic oesophagitis market to reach $1.19bn by 2030 With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow rapidly.
The study authors noted that an estimated 1 billion individuals are expected to have obesity by 2030. Obesity is defined as a body mass index (BMI) of 30.0 and higher.
The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).
The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7 LXE408 is currently entering Phase II clinical development.
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3 billion in 2030. billion by 2030, accounting for 80.11 CAGR through 2030 appeared first on Express Pharma. per cent, with sales projected to rise from $291 million in 2024 to $1.5
per cent expected from 2025 to 2030, the event will serve as a hub for Distributors, Procurement Managers, Product Development Experts, Regulatory Affairs Professionals, and R&D specialists. per cent and a forecasted value of USD 12 billion by 2030. In India, a nation of 1.4
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content